Drug intelligence / Profile preview

HEC137076

Development stage: Preclinical
Lead developer: Sunshine Lake Pharma
Modality: Small Molecules

Overview

HEC137076 is a small molecule new chemical entity (NCE) being developed by Sunshine Lake Pharma for the treatment of migraine. It acts as an agonist of the 5-hydroxytryptamine receptor 1F (5-HT1F). Unlike traditional triptans, which target 5-HT1B and 5-HT1D receptors and can cause vasoconstriction, 5-HT1F agonists (often referred to as ditans) are designed to provide migraine relief by inhibiting the trigeminal system without affecting blood vessel diameter, potentially offering a safer profile for patients with cardiovascular concerns. HEC137076 is currently in the preclinical stage of development.

Targets

Calcitonin gene-related peptide type 1 receptor

Beyond the preview

Go deeper on HEC137076.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEC137076.

Explore the full profile